Last reviewed · How we verify
NCT05820009: VIABILITY
GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis
NA trial testing GORE® VIABIL® Biliary Endoprosthesis in Pancreatitis, Chronic in 133 participants. Suspended.
1 August 2026
Quick facts
| Lead sponsor | W.L.Gore & Associates |
|---|---|
| Phase | NA |
| Status | Suspended |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 133 |
| Start date | 1 February 2024 |
| Primary completion | 1 August 2026 |
| Estimated completion | 1 August 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- GORE® VIABIL® Biliary Endoprosthesis
- GORE® VIABIL® Short Wire Biliary Endoprosthesis
Conditions studied
- Pancreatitis, Chronic — all drugs for Pancreatitis, Chronic →
- Stricture; Bile Duct — all drugs for Stricture; Bile Duct →
Sponsor
W.L.Gore & Associates — full company profile →
Who can join
18 and older, any sex, with Pancreatitis, Chronic or Stricture; Bile Duct. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the safety and effectiveness of the GORE® VIABIL® Biliary Endoprosthesis in the treatment of benign biliary strictures secondary to Chronic Pancreatitis (CP).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05820009
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pancreatitis, Chronic
Currently open trials in the same condition.
- NCT07171112 — Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis · Phase 2 · recruiting
- NCT07202559 — Indometacin With or Without Aggressive Intravenous Hydration to Prevent Pancreatitis After Pancreatic Extracorporeal Sho · NA · recruiting
- NCT06729996 — Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis Associated Diabetes Mellitus · Phase 2 · recruiting
- NCT06549725 — Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pa · NA · recruiting
- NCT06330441 — Pancreatic Cancer Screening in a Population at High Risk · NA · recruiting
Other W.L.Gore & Associates trials
Trials by the same sponsor.
- NCT07147569 — TAMBE Japan Post-Marketing Surveillance · recruiting
- NCT06827990 — GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections · NA · recruiting
- NCT06872905 — Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular · recruiting
- NCT06578741 — GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study · NA · enrolling by invitation
- NCT06174376 — Clinical Outcomes of the Gore Synthetic Cornea Device · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05820009 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by W.L.Gore & Associates
- Last refreshed: 29 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05820009.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing